Drugs / Bavituximab
Bavituximab
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01634685 | Aug 2012 → Oct 2015 | rectum adenocarcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01323062 | May 2011 → May 2014 | non-small cell lung carcinoma | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01288261 | Jan 2011 → May 2013 | Her2-receptor negative breast cancer, male breast carcinoma | University of Arizona | Completed | No outcome recorded |
| Phase 1 | NCT00503347 | Jul 2007 → Mar 2011 | HIV infectious disease, chronic hepatitis C virus infection | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00343525 | May 2006 → Jan 2007 | hepatitis C virus infection | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00128271 | Aug 2005 → Aug 2006 | chronic hepatitis C virus infection | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00129337 | Jun 2005 → Aug 2009 | neoplasm | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01335204 | Jun 2011 → Mar 2013 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01273948 | Jan 2011 → Jan 2012 | hepatitis C virus infection | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01264705 | Jan 2011 → Apr 2018 | hepatocellular carcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 213 trials · 1 met primary | ||||||
| Phase 2 | NCT05249569 | Nov → Dec 2022 | hepatocellular carcinoma | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT04150900 | Jan 2020 → Sep 2024 overdue | squamous cell carcinoma | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04099641 | Sep 2019 → Dec 2021 | gastric cancer, gastroesophageal cancer | OncXerna Theraputics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03519997 | Apr 2018 → Apr 2023 | hepatocellular carcinoma | David Hsieh | Completed | No outcome recorded |
| Phase 2 | NCT03139916 | Sep 2017 → Aug 2022 | glioblastoma | Massachusetts General Hospital | Completed | Met primary |
| Phase 2 | NCT02685306 | Mar 2016 → Apr 2017 | triple-negative breast carcinoma | Peregrine Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02673814 | Feb 2016 → Apr 2017 | non-small cell lung carcinoma | Peregrine Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01272791 | Jan 2011 → Feb 2013 | malignant pancreatic neoplasm | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01160601 | Jun 2010 → Jun 2013 | non-small cell lung carcinoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01138163 | Jun 2010 → Oct 2012 | non-small cell lung carcinoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00669565 | Jul 2008 → Jul 2010 | breast carcinoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00687817 | Jun 2008 → Jul 2010 | non-small cell lung carcinoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00669591 | Jan 2008 → Jun 2010 | breast cancer | Peregrine Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02651610 | Dec 2015 → Dec 2017 | breast cancer | Peregrine Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01999673 | Dec 2013 → Mar 2017 | non-small cell lung carcinoma | Peregrine Pharmaceuticals | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02989870 Background | Mar 2017 → Oct 2018 | hepatocellular carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01984255 Comparator | Apr 2014 → Apr 2016 | melanoma | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bavituximab | “Bavituximab 3mg/kg IVqwk (IV every week) x 14 plus ipilimumab 3mg/kg IVq3wk (IV every 3 weeks) x 4 or ipilimumab 3mg/kg IVq3wk x 4” NCT01984255 ↗ |
| Known as | CH3G4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742989 ↗ |
| Known as | TARVACIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742989 ↗ |
| Action | Inhibit | “Laboratory and animal studies have demonstrated that bavituximab specifically targets cancer cells and inhibits tumor growth in a variety of experimental cancer models.” NCT00129337 ↗ |
| Modality | Monoclonal antibody | “Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab)” NCT00128271 ↗ |
| Route | Intravenous | “bavituximab when administered via a vein as a single infusion” NCT00128271 ↗ |